Drugs that contain Brivaracetam
1. Drug name - BRIVIACT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(3 years from now) | |
| CN1740151A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Sep, 2007
(15 years ago) | |
| CN1740150A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Oct, 2007
(14 years ago) | |
| CN1303066C | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Jul, 2010
(12 years ago) | |
| CN1680314A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Jul, 2010
(12 years ago) | |
| CN1404470A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Apr, 2015
(7 years ago) | |
| CN1179944C | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Apr, 2015
(7 years ago) | |
| CN1404469A | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Feb, 2021
(1 year, 7 months ago) | |
| CN1208319C | UCB INC | 2-Oxo - -1 - Pyrrolidine Derivative, Preparation Method And Application Thereof |
Feb, 2021
(1 year, 7 months ago) | |
| IN200500340P3 | UCB INC | Compound Of General Formula (A) |
Feb, 2021
(1 year, 7 months ago) | |
| IN200201000P3 | UCB INC | A 2-Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts Thereof |
Feb, 2021
(1 year, 7 months ago) | |
| IN196025B | UCB INC | [2-Oxo-1-Pyrrolidine Derivatives] Process For Preparing |
Feb, 2021
(1 year, 7 months ago) | |
| IN200075B | UCB INC | A 2- Oxo-1-Pyrrolidine Compound Or Pharmaceutical Salts |
Feb, 2021
(1 year, 7 months ago) | |
| IN234848B | UCB INC | Compound Of General Formula (A) |
Feb, 2021
(1 year, 7 months ago) | |
| EP1447399B9 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1447399B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1447399A1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1477478A2 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses. |
Feb, 2021
(1 year, 7 months ago) | |
| EP1477478A3 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses. |
Feb, 2021
(1 year, 7 months ago) | |
| EP1265862A2 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1263727A1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1477478B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses. |
Feb, 2021
(1 year, 7 months ago) | |
| EP1265862B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Processes For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1263727B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivatives, Process For Preparing Them And Their Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1452524B1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| EP1452524A1 | UCB INC | 2-Oxo-1-Pyrrolidine Derivative And Its Pharmaceutical Uses |
Feb, 2021
(1 year, 7 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(7 years from now) | |
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/5ML (10MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.